The PPARγ2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy

Molecular Genetics and Metabolism

Volumn 94, Issue 3, 2008, Pages 347-351

  Jorsal, A ^a   Tarnow, L ^a   Lajer, M ^a   Ek, J ^a,b   Hansen, T ^a   Pedersen, O ^a,c   Parving, H H ^c,d  

^a STENO DIABETES CENTER   (Denmark)

^b JOHN F KENNEDY INSTITUTE   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d Rigshospitalet   (Denmark)

Author keywords

Cardiovascular disease; Diabetes; Diabetic nephropathy; End stage renal disease; Genetics; Glomerular filtration rate; Mortality; Pro12Ala

Indexed keywords

HEMOGLOBIN A1C; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIABETIC NEPHROPATHY; DISEASE DURATION; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KAPLAN MEIER METHOD; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS;

ADULT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 44649200427     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2008.03.014     Document Type: Article

References (31)

1. Borch-Johnsen K., Andersen P.K., and Deckert T. The effect of proteinuria on relative mortality in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28 (1985) 590-596
2. Borch-Johnsen K., and Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br. Med. J. 294 (1987) 1651-1654
3. Moczulski D.K., Rogus J.J., Antonellis A., Warram J.H., and Krolewski A.S. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q - results of novel discordant sib-pair analysis. Diabetes 47 (1998) 1164-1169
4. Imperatore G., Hanson R.L., Pettitt D.J., Kobes S., Bennett P.H., Knowler W.C., and the Pima Diabetes Genes Group. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Diabetes 47 (1998) 821-830
5. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 (1998) 507-514
6. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
7. Sarafidis P.A., and Bakris G.L. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 70 (2006) 1223-1233
8. Werman A., Hollenberg A., Solanes G., Bjorbaek C., Vidal-Puig A.J., and Flier J.S. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J. Biol. Chem. 272 (1997) 20230-20235
9. Deeb S.S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., Laakso M., Fujimoto W., and Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20 (1998) 284-287
10. Lohmueller K.E., Pearce C.L., Pike M., Lander E.S., and Hirschhorn J.N. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 33 (2003) 177-182
11. Doney A.S., Fischer B., Leese G., Morris A.D., and Palmer C.N. Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2403-2407
12. Herrmann S.M., Ringel J., Wang J.G., Staessen J.A., and Brand E. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin diabetes mellitus (BeDiaM) study. Diabetes 51 (2002) 2653-2657
13. Caramori M.L., Canani L.H., Costa L.A., and Gross J.L. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 52 (2003) 3010-3013
14. Eftychi C., Howson J.M., Barratt B.J., Vella A., Payne F., Smyth D.J., Twells R.C., Walker N.M., Rance H.E., Tuomilehto-Wolf E., Tuomilehto J., Undlien D.E., Ronningen K.S., Guja C., Ionescu-Tiirgoviste C., Savage D.A., and Todd J.A. Analysis of the type 2 diabetes-associated single nucleotide polymorphisms in the genes IRS1, KCNJ11, and PPARG2 in type 1 diabetes. Diabetes 53 (2004) 870-873
15. Johansen A., Jensen D.P., Bergholdt R., Mortensen H.B., Pociot F., Nerup J., Hansen T., and Pedersen O. IRS1, KCNJ11, PPARgamma2 and HNF-1alpha: do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1 and type 2 diabetes?. Diabetes Obes. Metab. 8 (2006) 75-82
16. Lajer M., Schjoedt K.J., Jacobsen P., Tarnow L., and Parving H.H. Aldosterone synthase (CYP11B2)-344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients. Diabet. Med. 23 (2006) 675-680
17. Parving H.-H., Østerby R., and Ritz E. Diabetic nephropathy. In: Brenner B.M. (Ed). The Kidney (2000), WB Saunders, Philadelphia 1731-1773
18. Vionnet N., Tregouet D., Kazeem G., Gut I., Groop P.H., Tarnow L., Parving H.H., Hadjadj S., Forsblom C., Farrall M., Gauguier D., Cox R., Matsuda F., Heath S., Thevard A., Rousseau R., Cambien F., Marre M., and Lathrop M. Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin gene. Diabetes 55 (2006) 3166-3174
19. Feldt-Rasmussen B., Dinesen B., and Deckert M. Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scand. J. Clin. Lab. Invest. 45 (1985) 539-544
20. Bröchner-Mortensen J., and Rödbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand. J. Clin. Lab. Invest. 36 (1976) 35-45
21. Parving H.-H., Jacobsen P., Tarnow L., Rossing P., Lecerf L., Poirier O., and Cambien F. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. Br. Med. J. 313 (1996) 591-594
22. Ek J., Urhammer S.A., Sorensen T.I., Andersen T., Auwerx J., and Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 42 (1999) 892-895
23. Ek J., Andersen G., Urhammer S.A., Hansen L., Carstensen B., Borch-Johnsen K., Drivsholm T., Berglund L., Hansen T., Lithell H., and Pedersen O. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44 (2001) 1170-1176
24. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Yusuf S., and Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
25. Tonjes A., Scholz M., Loeffler M., and Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29 (2006) 2489-2497
26. Christensen P.K., Larsen S., Horn T., Olsen S., and Parving H.-H. The causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. Kidney Int. 58 (2000) 1719-1731
27. Freely associating, Editorial, Nat. Genet. 22 (1999) 1-2.
28. Ludovico O., Pellegrini F., Di Paola R., Minenna A., Vaccaro O., Sesti G., and Trischitta V. The protective effect on the risk of type 2 diabetes given the PPARG2 Ala12 variant is heterogeneous across different populations. Diabetologia 49 Suppl. 1 (2006) 211-212
29. Li L., Cheng L.X., Nsenga R., He M.A., and Wu T.C. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin. Cardiol. 29 (2006) 300-304
30. Ridker P.M., Cook N.R., Cheng S., Erlich H.A., Lindpaintner K., Plutzky J., and Zee R.Y. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 859-863
31. Jacobsen P. Preventing end stage renal disease in diabetic patients: genetic aspects and dual blockade of the renin-angiotensin system. Dan. Med. Bull. (2004)